ライフサイエンスコーパス: tumor microenvironment

1 ersus immunosuppressive adenosine within the tumor microenvironment.

2 ate the phenotypic diversity of cells in the tumor microenvironment.

3 quires near-complete blockade of CD47 in the tumor microenvironment.

4 vulnerability to free oxygen species in the tumor microenvironment.

5 variety of primary tumors, independently of tumor microenvironment.

6 e checkpoints on individual cells within the tumor microenvironment.

7 d (ii) an inflammatory repolarization of the tumor microenvironment.

8 ming growth factor (TGF)-beta present in the tumor microenvironment.

9 e and immune cells as well as targets in the tumor microenvironment.

10 ion factors during adaptation to the hypoxic tumor microenvironment.

11 can cause cancer through alterations in the tumor microenvironment.

12 to configure protective immunity within the tumor microenvironment.

13 xP3(+) regulatory T cells (Tregs) within the tumor microenvironment.

14 sed heavily on local immune responses in the tumor microenvironment.

15 e to the heterogeneity and complexity of the tumor microenvironment.

16 es from RF-facilitated drug transport in the tumor microenvironment.

17 us unlikely to play an important role in the tumor microenvironment.

18 ts with NMIBC as a surrogate for the bladder tumor microenvironment.

19 enic therapy will involve alterations of the tumor microenvironment.

20 e of addressing complex issues involving the tumor microenvironment.

21 LC response to therapy while maintaining the tumor microenvironment.

22 nto tumors and form a major component of the tumor microenvironment.

23 critical component of the immunosuppressive tumor microenvironment.

24 h endothelial cells (E4(+)EC), mimicking the tumor microenvironment.

25 vasion or simply correlates with an inflamed tumor microenvironment.

26 fficacy of anti-PD-1 therapy by changing the tumor microenvironment.

27 l readout of the therapeutic response on the tumor microenvironment.

28 destly diminished the number of Tregs in the tumor microenvironment.

29 tform, which is specifically targeted to the tumor microenvironment.

30 pathway and innate immune suppression in the tumor microenvironment.

31 l, endothelial, and immune components of the tumor microenvironment.

32 munity by ameliorating the immunosuppressive tumor microenvironment.

33 D8(+) dendritic cells were identified in the tumor microenvironment.

34 stasis, following reconstitution, and in the tumor microenvironment.

35 elanomas are associated with an inflammatory tumor microenvironment.

36 d intratumoral heterogeneity and presence of tumor microenvironment.

37 (IRs) and suppressive mechanisms within the tumor microenvironment.

38 ng in both adjacent tumor cells and cells in tumor microenvironment.

39 s, indicating neutrophil polarization by the tumor microenvironment.

40 of tunneling nanotubes (TNTs) in the complex tumor microenvironment.

41 and myeloid-derived suppressor cells in the tumor microenvironment.

42 alyzing its effects on the components of the tumor microenvironment.

43 te IFNgamma production by T cells within the tumor microenvironment.

44 obtained from direct ex vivo analysis of the tumor microenvironment.

45 ction and the composition of the surrounding tumor microenvironment.

46 ulating the function of myeloid cells in the tumor microenvironment.

47 d breaks induced by TGFbeta expressed in the tumor microenvironment.

48 umor cell survival within the serum-depleted tumor microenvironment.

49 in and growth factor signals mediated by the tumor microenvironment.

50 ation and homogenous distribution within the tumor microenvironment.

51 cell types in the stromal compartment of the tumor microenvironment.

52 ovel readout of therapeutic influence on the tumor microenvironment.

53 ificantly decreased neutrophils in the colon tumor microenvironment.

54 o date, due in part to the immunosuppressive tumor microenvironment.

55 d ERK pathway and promotes angiogenesis in a tumor microenvironment.

56 ucose metabolism that could reflect distinct tumor microenvironment.

57 uppressive mechanism within the osteosarcoma tumor microenvironment.

58 induce a multitude of alterations within the tumor microenvironment.

59 ns that accumulate in circulation and in the tumor microenvironment.

60 differentiation of inflammatory cells in the tumor microenvironment.

61 They infiltrate into tumors and modulate the tumor microenvironment.

62 gulate tumor behavior, inflammation, and the tumor microenvironment.

63 D-1 pathway ligands (PD-L1 and PD-L2) in the tumor microenvironment.

64 a which these CAR T cells overcome a hostile tumor microenvironment.

65 of tissue-specific immune development in the tumor microenvironment.

66 ssociated with retention of TRM cells in the tumor microenvironment.

67 factor to mediate these effects of FTY720 in tumor microenvironment.

68 oid-derived suppressor cells (MDSC) into the tumor microenvironment.

69 ed in the expression profile of the cervical tumor microenvironment.

70 ytic myeloid-derived suppressor cells in the tumor microenvironment.

71 scin-C promotes cancer cell migration in the tumor microenvironment.

72 facilitating drug availability in the acidic tumor microenvironment.

73 may attenuate the Treg-mediated suppressive tumor microenvironment.

74 KL signaling network in stromal cells in the tumor microenvironment.

75 a tissue-engineered microvessel model of the tumor microenvironment.

76 se and fatty acid uptake directly within the tumor microenvironment.

77 egulatory (Treg) lymphocyte densities in the tumor microenvironment.

78 es the functional capabilities of T cells in tumor microenvironments.

79 atform to study anti-cancer therapeutics and tumor microenvironments.

80 egulate signaling pathways to adapt to harsh tumor microenvironments.

81 ll mechano-chemical perturbations that mimic tumor microenvironments.

82 promote cancer cell survival within TNF-rich tumor microenvironments.

83 expression in cancer cells can modulate the tumor microenvironment, a step critical for tumor progre

84 blockade of B7-H4 could favorably alter the tumor microenvironment allowing for antigen-specific cle

85 uids, play a critical role in modulating the tumor microenvironment and affecting the pathogenesis of

86 ession by: (i) inducing an immunosuppressive tumor microenvironment and angiogenesis via cytokine pro

87 The relative importance of the tumor microenvironment and cancer cell-intrinsic signali

88 ng as well as stress signals imparted by the tumor microenvironment and could be an important mechani

89 eveal the role of off-target drug effects on tumor microenvironment and development of acquired drug

90 demonstrating the capacity to manipulate the tumor microenvironment and enhance the progression of EB

91 Treg cell immunosuppressive activity in the tumor microenvironment and enhances anti-tumor T cell re

92 lications for understanding the logic of the tumor microenvironment and for improving therapeutic res

93 e data establish ZEB1 as a key factor in the tumor microenvironment and for maintaining TAMs' tumor-p

94 on characteristic of the poorly vascularized tumor microenvironment and has aided in the discovery of

95 on elaborated by melanoma cells dominate the tumor microenvironment and highlight the need to target

96 -1 receptor-positive immune effectors in the tumor microenvironment and induce PD-1 signaling and ass

97 xpression pattern of mutant IDH2 in the AITL tumor microenvironment and measure levels of 2HG in tiss

98 hat attempt to restrict 4-1BB agonism to the tumor microenvironment and minimize systemic exposure ha

99 ytes that are highly concentrated within the tumor microenvironment and never analyzed in the circula

100 at CAR T cells have to surmount in the solid tumor microenvironment and new approaches that are being

101 mas has unveiled a new aspect of the complex tumor microenvironment and new biomarkers.

102 ue type, the underlying cancer genetics, the tumor microenvironment and other variables such as diet

103 gnaling to regulate the immune status of the tumor microenvironment and support the strategic use of

104 e primary cells that internalized PLN in the tumor microenvironment and that PLN-induced tumor growth

105 C, RSPO3 is produced by stromal cells in the tumor microenvironment and the activating mutations appe

106 cell model system as they mimic the complex tumor microenvironment and thus have contributed to valu

107 In mice, ammonia accumulated in the tumor microenvironment and was used directly to generate

108 ue oxygenation is a driving parameter of the tumor microenvironment, and hypoxia can be a prognostic

109 omous pathways, the unique physiology of the tumor microenvironment, and interactions with non-cancer

110 tem cells (GSCs) are enriched in the hypoxic tumor microenvironment, and that monocarboxylate transpo

111 esin is required for iTreg conversion in the tumor microenvironment, and the deletion of moesin from

112 e efficacy of TSL treatment within different tumor microenvironments, and further advance our underst

113 Fibroblasts within the mammary tumor microenvironment are active participants in carcin

114 rious factors and cellular components in the tumor microenvironment are key drivers associated with d

115 However, their potential effects on the tumor microenvironment are largely unknown.

116 the biology of gammadeltaT17cells within the tumor microenvironment are less well understood.

117 ns of LDH-A and lactate by macrophage in the tumor microenvironment are major drivers of T-cell immun

118 , but the contributing conditions within the tumor microenvironment are not well understood.

119 viewed as a target of great relevance in the tumor microenvironment, because of their important role

120 tudy, we developed a biomimetic microfluidic tumor microenvironment (bMTM) comprising co-culture of t

121 proportion of infiltrating leukocytes in the tumor microenvironment but altered the phenotype of myel

122 to investigate leukocyte trafficking in the tumor microenvironment, but parameterizing such models i

123 hages enhance invasion and metastasis in the tumor microenvironment, but the basis for their effects

124 t newly formed nerve fibers may regulate the tumor microenvironment, but their exact functions are un

125 Cells adjust to hypoxic stress within the tumor microenvironment by downregulating energy-consumin

126 the PD1/PDL1 pathway specifically within the tumor microenvironment by secreting a soluble form of PD

127 c Contrast Enhanced (DCE-)MRI can depict the tumor microenvironments by identifying areas with variab

128 unique pathophysiological signatures in the tumor microenvironment, can severely limit the utility o

129 mmunogenicity and a strong immunosuppressive tumor microenvironment cause significant intrinsic resis

130 of TNFalpha to promote an immune-suppressive tumor microenvironment characterized by an abundance of

131 is associated with immunosuppression in the tumor microenvironment, compared with oAd+DC.

132 s yields high resolution 3D maps of multiple tumor microenvironment components and biomarkers through

133 The inflammatory tumor microenvironment contributes to metastasis, for in

134 Our findings not only shed light on how the tumor microenvironment contributes to premetastatic nich

135 ng in brain tumors is also influenced by the tumor microenvironment contributing to drug resistance a

136 The properties of the tumor microenvironment control T-cell infiltration, dist

137 ng, suggesting a mechanism through which the tumor microenvironment controls tumor progression and en

138 As uncovered in recent studies, the tumor microenvironment could be modulated by various nan

139 of CAF-induced CXCL12, IL6 and VEGFA within tumor microenvironment could enable peritoneal metastasi

140 infiltration of neutrophils by manipulating tumor microenvironments could be a novel strategy to act

141 Here we report that the tumor microenvironment creates an immunosuppressive sign

142 ay between tumor cells and host cells in the tumor microenvironment dictates the development of all c

143 ndicate that lack of CD103(+) DCs within the tumor microenvironment dominantly resists the effector p

144 D40L by the transcription factor GLI2 in the tumor microenvironment downstream of CCR3 signaling.

145 radiotherapy, and the potential to overcome tumor microenvironment-driven immunosuppression is being

146 We will discuss how tumor microenvironment-driven transient compositional tu

147 Our findings show how the tumor microenvironment drives the acquisition of CD39 as

148 xcessive hyaluronan (HA) accumulation in the tumor microenvironment, elevating interstitial pressure

149 rs of vaccine-induced CD8 T cells within the tumor microenvironment, eliciting potent antitumor effic

150 notherapeutic intervention.Significance: The tumor microenvironment elicits a subset of functionally

151 Remodeling of tumor microenvironments enables enhanced delivery of nan

152 reprograms monocytes and macrophages in the tumor microenvironment, encouraging the clinical use of

153 As a result, complement activation in the tumor microenvironment enhances tumor growth and increas

154 ys in tumor cells help produce a suppressive tumor microenvironment enriched for inhibitory cells, po

155 Targeting the hypoxic tumor microenvironment has a broad impact in cancer epig

156 raphical organization of collagen within the tumor microenvironment has been implicated in modulating

157 The tumor microenvironment has been widely exploited as an a

158 The tumor microenvironment has recently been shown to play d

159 Endothelial cells (ECs) in the tumor microenvironment have been reported to play a more

160 t meeting themes included immunology and the tumor microenvironment, heterogeneity of both the epithe

161 Tregs in the tumor microenvironment highly expressed PD-1 and were re

162 ibodies, and antibody fragments to image the tumor microenvironment, immune status, and changes over

163 n clinical trials, genetics and epigenetics, tumor microenvironment, immune suppression, metastasis,

164 ovel molecular targets for the abrogation of tumor microenvironment immunosuppression.

165 ults in reduced T cell infiltration into the tumor microenvironment, implicating NSD1 as a tumor cell

166 moral gammadelta T cells are abundant in the tumor microenvironment in both mouse and human.

167 opinion on the importance of exploiting the tumor microenvironment in cancer therapy, and how this c

168 and metastasis and consider the role of the tumor microenvironment in engendering heterogeneity and

169 the acquisition of a pro-inflammatory, anti-tumor microenvironment in mouse brain.

170 larify the role of the NF1-haploinsufficient tumor microenvironment in MPNST.

171 role for loss of HBEGF in the neuroblastoma tumor microenvironment in neuroblastoma pathogenesis.-Ga

172 esence and functional orientation within the tumor microenvironment in non-small cell lung cancer (NS

173 R2 rapidly formed tumors outside the primary tumor microenvironment in nude mice, exhibited signature

174 es to the production of an immunosuppressive tumor microenvironment in pancreatic cancer.

175 trend of increased expression in PD-1 in the tumor microenvironment in patients who had confirmed res

176 technologies and methods for analysis of the tumor microenvironment in patients with GBM.

177 that can simulate cellular migration in the tumor microenvironment in response to a chemoattractant

178 Nerves are a notable feature of the tumor microenvironment in some epithelial tumors, but th

179 The importance of the tumor microenvironment in targeted anticancer therapies

180 Functionally, KPNA4 alters tumor microenvironment in terms of macrophage polarizati

181 cues, providing insight into the role of the tumor microenvironment in the origin and treatment of Ra

182 enting an in-depth human atlas of the immune tumor microenvironment in this disease.

183 We investigated remodeling of the tumor microenvironment in transgenic Ntva glioblastoma m

184 tion with various cellular components of the tumor microenvironment including platelets is crucial fo

185 s indicate that the bMTM platform mimics the tumor microenvironment including the EPR effect.

186 targeted delivery of a TLR7/8 agonist to the tumor microenvironment, increasing the proportion of tum

187 -risk HPV oncogenes profoundly reprogram the tumor microenvironment independently of and synergistica

188 metabolites consumed and secreted within the tumor microenvironment induce tumor-associated macrophag

189 imuli, increased stiffness of the ECM in the tumor microenvironment induces differentiation of MSC to

190 Gene signature-based tumor microenvironment inference revealed a decrease in

191 In a coclinical trial to examine how the tumor microenvironment influences the response to multia

192 doses; however, PD-1 upregulation within the tumor microenvironment inhibited T cell function.

193 vidence that the recruitment of Tregs to the tumor microenvironment inhibits an effective antitumor i

194 eloid-derived suppressor cells (MDSC) in the tumor microenvironment, initially reduced by BRAFi treat

195 fusion-weighted MRI (DW-MRI) to separate the tumor microenvironment into relevant tissue compartments

196 derstood ECM composition of the fibrotic and tumor microenvironment is an underexplored source of dia

197 orted that estrogen signaling in the stromal tumor microenvironment is associated with cervical cance

198 The tumor microenvironment is characterized by nutrient-depr

199 D) cell culture approaches, where the native tumor microenvironment is difficult to recapitulate.

200 The tumor microenvironment is highly heterogeneous.

201 The tumor microenvironment is known to be essential for meta

202 ion of programmed cell death-1 (PD-1) in the tumor microenvironment is known to inhibit effective ada

203 rough exclusion of effector T cells from the tumor microenvironment is not known.

204 therapeutic targets derived from the hypoxic tumor microenvironment is of major importance.

205 ally active but how this trait may alter the tumor microenvironment is poorly understood.

206 quency and functional orientation within the tumor microenvironment is regulated by beta2-adrenergic

207 ecause the adaptation of cancer cells to the tumor microenvironment is vital for subsequent oncogenes

208 Our results reveal how LCN2 acts in the tumor microenvironment links obesity, inflammation, and

209 r interactions in the context of the hypoxic tumor microenvironment may be important in preventing or

210 e hypothesize that specific targeting of the tumor microenvironment may constitute an alternative or

211 cancer suggest that neural modulation of the tumor microenvironment may prove a universal theme, alth

212 Immune cells in the tumor microenvironment modulate cancer progression and a

213 during tumor progression, clarifying how the tumor microenvironment modulates ECM homeostasis control

214 Over the past 10 years, the Tumor Microenvironment Network (TMEN), supported by the

215 Tumor microenvironment of metastasis (TMEM), a three-cel

216 d progression to micrometastases; as well as tumor microenvironment of metastasis function, the hallm

217 ry tumor, PTX increased the abundance of the tumor microenvironment of metastasis, a landmark microan

218 t to a new type of protumorigenic CAF in the tumor microenvironment of neuroblastoma and to STAT3 and

219 thod could ultimately, by characterizing the tumor microenvironment of patients who have been treated

220 To address this problem, we developed the Tumor-microenvironment-on-chip (T-MOC), a new microfluid

221 esized that host-derived TPO, present in the tumor microenvironment, or pharmacological c-MPL agonist

222 The tumor microenvironment plays an important role in the pr

223 The tumor microenvironment plays an important role in tumor

224 ti-lncRNA to the acidic (pH approximately 6) tumor microenvironment, PNAs were conjugated to pH-low i

225 The tumor microenvironment presents metabolic constraints to

226 LCAM expression in cells forming the stromal tumor microenvironment profoundly affected lung tumor gr

227 w tumor cell deposition of tenascin-C in the tumor microenvironment promotes invasive migration and m

228 llular matrix glycoprotein tenascin-C in the tumor microenvironment promotes invasive migration and m

229 B cell growth, indicating that CD40L in the tumor microenvironment promotes malignant B cell activat

230 erefore, reprogramming of PGE2 metabolism in tumor microenvironment provides an opportunity to reduce

231 see applications in phenotyping cells within tumor microenvironments, recognizing tumor boundaries, i

232 leiotropic tumor suppressor, but its role in tumor microenvironment regulation is poorly characterize

233 ntrolled and connected upon challenge by the tumor microenvironment remains unclear.

234 to its products, the function of 5-LO in the tumor microenvironment remains unclear.

235 g cells behave in the metabolically abnormal tumor microenvironment remains unknown.

236 essed specifically in osteoblasts, while the tumor microenvironment remains wild type for p53, allowi

237 progression: modulation of immune response, tumor microenvironment reprogramming, and metastasis.

238 d to chromatin remodeling, inflammation, and tumor microenvironment restructuring.

239 However, persistent antigen exposure in the tumor microenvironment results in sustained LAG3 express

240 Communication between cancer cells and the tumor microenvironment results in the modulation of comp

241 of therapy-sensitive tumors in heterogeneous tumor microenvironments results in apoptosis of therapy-

242 We have showed preferential BTZ release in tumor-microenvironment, specific binding to MM cells, an

243 ampered by elements of the immunosuppressive tumor microenvironment such as TGFbeta.

244 eg depletion provoked drastic changes in the tumor microenvironment, such as strong infiltration of C

245 implications of our findings in analyses of tumor microenvironment, suggesting that as tumor cell ge

246 ering an immunosuppressive and prometastatic tumor microenvironment, suggesting the potential of immu

247 The tumor microenvironment supplies proinflammatory cytokine

248 we show that bone marrow adipocytes from the tumor microenvironment support the survival and prolifer

249 to low nutrient and oxygen conditions in the tumor microenvironment that enables cancer cells of dive

250 acrophages are prominent immune cells in the tumor microenvironment that exert potent effects on canc

251 he physical and biological parameters of the tumor microenvironment that mediate intravasation of tum

252 apies is attributed to the immunosuppressive tumor microenvironment that protects malignant cells fro

253 oblasts (CAFs), which are a key component of tumor microenvironment that provides necessary support f

254 very barriers for nano-carriers presented in tumor microenvironment, the characteristics and formatio

255 e, we discuss the unique properties of GBM's tumor microenvironment, the effects of GBM standard on c

256 ecruited to inflammatory sites or in certain tumor microenvironments, the trafficking properties of p

257 D3 terminates TH action within the tumor microenvironment, thereby enhancing cancer cell pr

258 Thus, endothelial E-selectin shapes the tumor microenvironment through the recruitment, adhesion

259 Therefore, targeting p53 in the tumor microenvironment (TME) also represents an immunolo

260 te to the growth-promoting attributes of the tumor microenvironment (TME) and bias immunity toward ty

261 adapt to the metabolic constrains within the tumor microenvironment (TME) and to what degree this aff

262 While it is clear that the tumor microenvironment (TME) contributes to cancer cell

263 The tumor microenvironment (TME) in pancreatic ductal adenoc

264 T-cell exclusion from the tumor microenvironment (TME) is a major barrier to overc

265 ography of PD-L1(+) and PD-1(+) cells in the tumor microenvironment (TME) of cHL.

266 Noninvasive in vivo assessment of chemical tumor microenvironment (TME) parameters such as oxygen (

267 years, but the precise dynamics between the tumor microenvironment (TME), nontumor microenvironment

268 lls, especially inside the immunosuppressive tumor microenvironment (TME), the efficacy of adoptive c

269 Here, we show that in the human breast tumor microenvironment (TME), the presence of increased

270 mor cell-intrinsic mechanisms in addition to tumor microenvironment (TME)-mediated extrinsic resistan

271 ather than extrinsic mechanisms based in the tumor microenvironment (TME).

272 nant cells as well as the composition of the tumor microenvironment (TME).

273 to the development of an immune-suppressive tumor microenvironment (TME).

274 ion and hypoxic stress, two hallmarks of the tumor microenvironment (TME).

275 to autocrine and paracrine functions in the tumor microenvironment (TME).

276 iated fibroblasts (CAFs) and fibrosis in its tumor microenvironment (TME).

277 the presence of a uniquely immunosuppressive tumor microenvironment (TME).

278 works and potential druggable targets across tumor microenvironments (TMEs), we utilized 5-ALA fluore

279 s that mitigate T-cell inhibition within the tumor microenvironment to improve immunotherapy of solid

280 effects, impacting endothelial cells of the tumor microenvironment to promote tumor angiogenesis.

281 gy can relieve drug delivery barriers in the tumor microenvironment to safely widen the therapeutic w

282 RAGE by multiple approaches in the tumor and tumor microenvironment, to inhibit the metastatic proces

283 oxia, which reprograms the immunosuppressive tumor microenvironment toward immunostimulation and impr

284 ion by a subset of regulatory T cells in the tumor microenvironment triggers Treg instability locally

285 or cells (EGFR in cancer cell membranes) and tumor microenvironments (VEGF in the extracellular matri

286 t of effector CD4+ and CD8+ T cells into the tumor microenvironment via a C-X-C motif chemokine ligan

287 and the role of 5-LO and its products in the tumor microenvironment, we analyzed its expression and f

288 l immune-inhibitory pathways in the prostate-tumor microenvironment, we evaluated untreated and ipili

289 Nerves in the tumor microenvironment were positive for TrkA.

290 proinflammatory cytokines in PSC of the PDAC tumor microenvironment, whereas downregulation of LCN2-s

291 o an immunosuppressive cytokine and cellular tumor microenvironment which suppresses adoptively trans

292 nism of acquired drug resistance through the tumor microenvironment, which is mediated by human tumor

293 ve understanding of nano-bio interactions in tumor microenvironments, which are characterized by dens

294 lium, mediating cellular accumulation in the tumor microenvironment while decreasing vascular barrier

295 D8(+) T and natural killer (NK) cells in the tumor microenvironment, while reducing tumor burden and

296 To capture the cellular interactions of the tumor microenvironment with high-resolution imaging, we

297 rsion of tumors to an immunologically active tumor microenvironment with increased intratumoral frequ

298 Opioids modulate the tumor microenvironment with potential functional consequ

299 mechanistically linked obesity and an obese tumor microenvironment with signaling pathways that pred

300 of their immunosuppressive functions in the tumor microenvironment, with potentially broad therapeut